Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 93-2513996

CURE MAPT FTD

Tax-exempt · DENVER, CO 80220

Financials

$44K$31K2025
Revenue Expenses · by fiscal year end
Financials of CURE MAPT FTD by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990$44,297$30,751$13,546$15,927$0$15,927
Financial details: 990 for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$44,297
Program service revenue
$0
Investment income
$0
Other revenue
$0

Expenses

Grants and similar amounts paid
$0
Compensation of officers, directors and key employees
$0
Salaries, compensation and benefits (total)
$0
Professional fundraising fees
$0
Legal fees
$50
Travel
$10,581
Program services (functional)
$22,566
Management and general (functional)
$8,185

Balance sheet and other

Total assets, start of year
$2,381
Total assets, end of year
$15,927
Total liabilities, end of year
$0
Net assets, end of year
$15,927
Gross receipts
$44,297
Employees
0
Volunteers
47
Year formed
2023
State of legal domicile
CO

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensation
Barbara FrommellChair
Trustee or director, Officer
10$0
Barbara DawsonVice Chair
Trustee or director, Officer
15$0
David FrommellSecretary
Trustee or director, Officer
10$0
Michael KingTreasurer
Trustee or director, Officer
10$0
Tanya SteelOperations and Communications Director
Trustee or director
20$0

Address and contacts

Address (IRS master file)
4035 E 18TH AVE, DENVER, CO 80220-1016
Mailing address (990-N for 2023)
4035 E 18th Avenue, Denver CO 80220
Principal officer (990 for 2025)
Barbara Frommell, 4035 E 18th Ave, Denver, CO 80220
Principal officer (990-N for 2023)
Barbara Frommell, 4035 E 18th Avenue, Denver CO 80220
Signed the 990
Michael King, Treasurer
Phone
(720) 432-1352

Mission

Cure MAPT FTD increases awareness of the brain disease commonly known as frontotemporal dementia (FTD), of the importance of genetic testing, and specifically of the disease caused by a mutation of the MAPT (microtubule-associated protein tau) gene. Through regular meetings with our volunteer Scientific Advisory Board and active members, we ensure open communication, strong advocacy, and unwavering support for the MAPT community in an effort to find a cure. We actively participate in medical and scientific conferences that are focused on the genetics of FTD and dementia-related issues. Cure MAPT FTD advocates for MAPT-specific trials and access to other FTD gene-specific trials. Currently there are no interventional, drug or gene therapy trials that are available for MAPT patients, regardless of symptom status. We actively participate in key scientific conferences worldwide, building vital connections with researchers and fostering collaboration.

990 for the year ended December 31, 2025

Program accomplishments

  • We significantly increased awareness of the brain disease commonly known as frontotemporal dementia ("FTD"), created by a mutation of the MAPT (or Microtubule-Associated Protein Tau) by actively participating, speaking at and/or sponsoring conferences that are focused on dementia. The conferences included the Alzheimer's Drug Discovery Foundation's first annual Scientific Summit, Palm Beach, FL, the Tau Global 2025 Conference in London, England, the AFTD Education Conference, in Denver, Colorado, and the Alzheimer's Association International Conference (AAIC) in Toronto, CA.
    Expenses $12,846
  • We participated in a FDA Patient Listening Session in May 2025 which gave MAPT FTD persons and caregivers a direct platform to share their lived experiences with federal regulators and the research community. We advocated at the session, as well as at conferences, and throughout the year with the global scientific and pharma community, for MAPT-specific trials and access to other FTD gene-and tau-specific trials. To accelerate this progress, we've launched a global survey and HIPPA compliant database of individuals with MAPT mutations, making it easier for scientists to identify potential participants for clinical trials.
    Expenses $9,720
  • As part of our mission, we provided both personal and organizational support to FTD patients and their families. This included support-group meetings, educational materials, genetic testing information, conference reimbursement, and opportunities to interface with the broader scientific community.0

What it must file and when

IRS records say it files Form 990-N (e-Postcard). Gross receipts normally $50,000 or less. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990 on file
2024December 31, 2024May 15, 2025Check at the IRS
2023December 31, 2023May 15, 2024990-N on file

File the 2026 990-N for CURE MAPT FTD

Due May 17, 2027 · e-filed with the IRS by 990.tax, an IRS-authorized e-file provider

IRS record

EIN
93-2513996
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2026
Accounting year ends
December
Files
Form 990-N (e-Postcard)
Category (NTEE)
Medical research (H01)
Assets (IRS master file)
$15,927
Income (IRS master file)
$44,297

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2025$44,297$30,751$15,927IRS
990-N for 2023
Officer: Barbara Frommell
December 31, 2023≤ $50,000 receipts––e-Postcard

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 93-2513996).

Questions about CURE MAPT FTD

What is the EIN of CURE MAPT FTD?
The employer identification number (EIN) of CURE MAPT FTD is 93-2513996.
Is CURE MAPT FTD tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2026.
Are donations to CURE MAPT FTD tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does CURE MAPT FTD file?
Form 990-N (e-Postcard). Gross receipts normally $50,000 or less.
When is the next return of CURE MAPT FTD due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did CURE MAPT FTD last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2025.
Who is the principal officer of CURE MAPT FTD?
The 990 for the year ended December 31, 2025 names Barbara Frommell.
Who are the officers and directors of CURE MAPT FTD?
The 990 for the year ended December 31, 2025 lists 5 people; 0 received compensation from the organization.
How much revenue does CURE MAPT FTD have?
On its 990 for the year ended December 31, 2025 it reported revenue of $44,297, expenses of $30,751 and total assets of $15,927 at year end.

Other nonprofits in DENVER

All nonprofits in DENVER · Colorado · Medical research